Book Chapter

Tumor Resistance Mechanisms to Inhibitors Targeting the Epidermal Growth Factor Receptor – Part II: Intracellular Molecules

R Luwor

Frontiers in Clinical Drug Research - Anti-Cancer Agents, Volume 3 | Bentham eBooks | Published : 2016


Tumor resistance to agents targeting the Epidermal Growth Factor Receptor (EGFR) is common, and well recognised as a major challenge to successful clinical outcome, because patients often present with tumors that contain pre-existing intrinsic resistance mechanisms to current EGFR inhibitors, which ultimately has no therapeutic benefit. Furthermore, patients who initially respond to these therapies commonly relapse, presenting with new tumors that have acquired resistance to the original therapy. Substantial translational and clinical research has been undertaken in order to understand, and more importantly overcome, the molecular initiators of both intrinsic and acquired tumor resistance. H..

View full abstract